Department of Translational Medicine, Section of Pediatrics, University of Naples "Federico II", Naples, Italy.
Section of Metabolic Diseases, Beatrix Children's Hospital, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.
J Inherit Metab Dis. 2020 Jul;43(4):770-777. doi: 10.1002/jimd.12224. Epub 2020 Feb 26.
A potential role of dietary lipids in the management of hepatic glycogen storage diseases (GSDs) has been proposed, but no consensus on management guidelines exists. The aim of this study was to describe current experiences with dietary lipid manipulations in hepatic GSD patients. An international study was set up to identify published and unpublished cases describing hepatic GSD patients with a dietary lipid manipulation. A literature search was performed according to the Cochrane Collaboration methodology through PubMed and EMBASE (up to December 2018). All delegates who attended the dietetics session at the IGSD2017, Groningen were invited to share unpublished cases. Due to multiple biases, only data on GSDIII were presented. A total of 28 cases with GSDIII and a dietary lipid manipulation were identified. Main indications were cardiomyopathy and/or myopathy. A high fat diet was the most common dietary lipid manipulation. A decline in creatine kinase concentrations (n = 19, P < .001) and a decrease in cardiac hypertrophy in paediatric GSDIIIa patients (n = 7, P < .01) were observed after the introduction with a high fat diet. This study presents an international cohort of GSDIII patients with different dietary lipid manipulations. High fat diet may be beneficial in paediatric GSDIIIa patients with cardiac hypertrophy, but careful long-term monitoring for potential complications is warranted, such as growth restriction, liver inflammation, and hepatocellular carcinoma development.
已经提出了膳食脂质在治疗肝糖原贮积病(GSD)中的潜在作用,但目前尚无关于管理指南的共识。本研究旨在描述目前对肝 GSD 患者进行膳食脂质操作的经验。成立了一项国际研究,以确定描述肝 GSD 患者进行膳食脂质操作的已发表和未发表的病例。根据 Cochrane 协作方法,通过 PubMed 和 EMBASE(截至 2018 年 12 月)进行了文献检索。邀请参加 2017 年 IGSD 在格罗宁根举行的营养会议的所有代表分享未发表的病例。由于存在多种偏倚,仅呈现了关于 GSDIII 的数据。共确定了 28 例 GSDIII 并进行了膳食脂质操作。主要适应症为心肌病和/或肌病。高脂肪饮食是最常见的膳食脂质操作。在引入高脂肪饮食后,观察到肌酸激酶浓度下降(n = 19,P <.001)和儿科 GSDIIIa 患者心脏肥大减少(n = 7,P <.01)。本研究介绍了具有不同膳食脂质操作的 GSDIII 患者的国际队列。高脂肪饮食可能对伴有心脏肥大的儿科 GSDIIIa 患者有益,但需要仔细进行长期监测以预防潜在并发症,例如生长受限、肝脏炎症和肝细胞癌的发展。